Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Website: cyclerion.com



Growth: Good revenue growth rate 100.0%, there is acceleration compared to average historical growth rates 37.5%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1 050.0%. On average the margin is decreasing steadily. Gross margin is low, -1 778.5%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 50% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -1 273.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 25.4% higher than minimum and 90.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -46.8x by EV / Sales multiple

Key Financials (Download financials)

Ticker: CYCN
Share price, USD:  (0.0%)1.48
year average price 2.3889  


year start price 3.1200 2025-02-15

max close price 3.7000 2025-04-28

min close price 1.1800 2025-12-30

current price 1.4800 2026-02-14
Common stocks: 2 176 050

Dividend Yield:  0.0%
EV / Sales: -2.4x
Margin (EBITDA LTM / Revenue): -1 050.0%
Fundamental value created in LTM:
Market Cap ($m): 3
Net Debt ($m): -13
EV (Enterprise Value): -10
Price to Book: 0.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-09-24seekingalpha.com

Cyclerion Therapeutics, Inc. - Pre Recorded Special Call

2024-12-17globenewswire.com

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

2024-08-07globenewswire.com

Regina Graul, Ph.D., Promoted to Chief Executive Officer
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-05 2024-11-14 2024-08-07 2024-05-07 2023-11-13 2023-07-28 2023-05-12 2022-11-03
acceptedDate 2025-11-12 16:30:53 2025-08-05 16:30:55 2025-03-04 16:15:24 2024-11-14 16:30:24 2024-08-07 06:45:21 2024-05-07 16:30:34 2024-03-05 16:15:38 2023-11-13 16:30:32 2023-07-28 16:48:38 2023-05-11 19:37:17 2023-03-22 16:55:38 2022-11-03 17:00:58 2022-02-24 16:06:04 2021-02-25 07:35:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 875 000 93 000 2M 194 000 0 0 0 0 0 0 297 000 0 3M 2M
costOfRevenue 0 0 0 0 0 0 0 0 0 0 6M 0 0 56M
grossProfit 875 000 93 000 2M 194 000 0 0 0 0 0 0 -5M 0 3M -54M
grossProfitRatio 1 1 1 0 0 0 0 0 0
researchAndDevelopmentExpenses 348 000 56 000 286 000 81 000 105 000 44 000 2M 580 000 886 000 4M 6M 7M 38M 56M
generalAndAdministrativeExpenses 2M 2M 5M 1M 1M 2M 8M 2M 3M 3M 13M 4M 21M 29M
sellingAndMarketingExpenses 0 0 0 0 0 0 200 000 0 0 0 400 000 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 2M 5M 1M 1M 2M 8M 2M 3M 3M 13M 4M 21M 29M
otherExpenses 0 0 0 0 0 0 3M 0 0 0 -6M 0 259 000 -58M
operatingExpenses 2M 2M 6M 1M 1M 2M 13M 3M 4M 7M 13M 11M 59M 27M
costAndExpenses 2M 2M 6M 1M 1M 2M 13M 3M 4M 7M 19M 11M 59M 84M
interestIncome 30 000 31 000 208 000 42 000 62 000 76 000 358 000 107 000 62 000 0 294 000 0 0 588 000
interestExpense 0 0 0 0 0 0 0 0 0 88 000 0 111 000 16 000 0
depreciationAndAmortization 0 0 0 0 0 43 276 65 000 7M 0 0 65 000 0 472 000 2M
ebitda -976 000 -2M -4M -1M -1M -2M -10M 593 000 -4M -7M -18M -11M -54M -81M
ebitdaratio -1.115 -17.978 -5.814 0 0 0 0 0 0
operatingIncome -1M -2M -4M -1M -1M -2M -13M -6M -4M -7M -19M -11M -55M -81M
operatingIncomeRatio -1.15 -17.978 -5.814 0 0 0 0 0 0
totalOtherIncomeExpensesNet 30 000 1M 571 000 405 000 62 000 76 000 358 000 -3M 62 000 88 000 294 000 111 000 4M 3M
incomeBeforeTax -976 000 -324 000 -3M -723 000 -1M -2M -13M -6M -4M -7M -18M -10M -52M -78M
incomeBeforeTaxRatio -1.115 -3.484 -3.727 0 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 -43 276 0 -17M 0 -176 000 0 -222 000 0 0
netIncome -976 000 -324 000 -3M -723 000 -1M -2M -5M 8M -4M -7M -44M -10M -52M -78M
netIncomeRatio -1.115 -3.484 -3.727 0 0 0 0 0 0
eps -0.3 -0.11 -1.21 -0.29 -0.53 -0.62 -8.99 -3.36 -1.83 -3.11 -20.15 -0.24 -26.4 -47.8
epsdiluted -0.3 -0.11 -0.29 -0.53 -0.62 -3.36 -1.83 -3.11 -0.24
weightedAverageShsOut 3M 3M 3M 3M 3M 2M 2M 2M 2M 2M 2M 43M 2M 2M
weightedAverageShsOutDil 3M 3M 3M 3M 3M 2M 2M 2M 2M 2M 2M 43M 2M 2M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-05 2023-03-22 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 208 000 358 000 294 000 -16 000 588 000
ebit -4M -10M -19M -54M -83M
nonOperatingIncomeExcludingInterest 0 -3M 0 -881 000 2M
netIncomeFromContinuingOperations -3M -13M -18M -52M -78M
netIncomeFromDiscontinuedOperations 0 7M -26M 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -3M -13M -18M -52M -78M
epsDiluted -1.21 -8.99 -20.15 -26.4 -47.8

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-05 2024-11-14 2024-08-07 2024-05-07 2023-11-13 2023-07-28 2023-05-12 2022-11-03
acceptedDate 2025-11-12 16:30:53 2025-08-05 16:30:55 2025-03-04 16:15:24 2024-11-14 16:30:24 2024-08-07 06:45:21 2024-05-07 16:30:34 2024-03-05 16:15:38 2023-11-13 16:30:32 2023-07-28 16:48:38 2023-05-11 19:37:17 2023-03-22 16:55:38 2022-11-03 17:00:58 2022-02-24 16:06:04 2021-02-25 07:35:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 5M 3M 3M 3M 5M 6M 8M 9M 6M 7M 13M 20M 54M 54M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 5M 3M 3M 3M 5M 6M 8M 9M 6M 7M 13M 20M 54M 54M
netReceivables 100 000 525 000 556 000 44 000 0 0 0 0 0 96 000 96 000 227 000 100 000 127 000
inventory 0 0 0 0 0 0 0 0 0 567 000 0 0 928 000 0
otherCurrentAssets 397 000 489 000 16 000 632 000 127 000 318 000 11 000 30 000 428 000 503 000 537 000 488 000 468 000 2M
totalCurrentAssets 5M 4M 4M 4M 5M 6M 8M 10M 7M 8M 15M 22M 55M 59M
propertyPlantEquipmentNet 0 0 0 0 0 0 0 0 1M 1M 1M 1M 1M 50M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 5M 5M 5M 5M 5M 5M 5M 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 5M 0 0 0 0 0 0 0 2M 2M 2M 2M 2M 7M
totalNonCurrentAssets 5M 5M 5M 5M 5M 5M 5M 5M 3M 3M 3M 3M 4M 57M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 10M 9M 10M 9M 10M 11M 13M 15M 10M 11M 18M 25M 59M 115M
accountPayables 480 000 462 000 390 000 304 000 651 000 741 000 1M 814 000 2M 4M 3M 2M 2M 1M
shortTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 4M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 397 000 338 000 63 000 396 000 631 000 700 000 102 000 2M 3M 4M 68 000 7M 7M 176 000
totalCurrentLiabilities 877 000 800 000 725 000 700 000 1M 1M 2M 2M 5M 8M 8M 9M 11M 17M
longTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 4M 0 -2M 0 0
totalNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 4M 0 2M 0 39M
otherLiabilities 0 0 0 0 0 0 0 0 0 -4M 0 -2M 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0 42M
totalLiabilities 877 000 800 000 725 000 700 000 1M 1M 2M 2M 5M 8M 8M 9M 11M 56M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
retainedEarnings -270M -269M -267M -268M -267M -266M -264M -263M -270M -266M -259M -252M -215M -163M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 -16 000 -12 000 -18 000 -16 000 -19 000 -20 000 -28 000 -23 000 -27 000
othertotalStockholdersEquity 280M 278M 276M 276M 276M 276M 275M 270M 268M
totalStockholdersEquity 10M 9M 9M 8M 9M 10M 11M 13M 5M 4M 10M 17M 48M 59M
totalEquity 10M 9M 9M 8M 9M 10M 11M 13M 5M 4M 10M 17M 48M 59M
totalLiabilitiesAndStockholdersEquity 10M 9M 9M 10M 11M 15M 10M 11M 25M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 10M 9M 10M 9M 10M 11M 13M 15M 10M 11M 18M 25M 59M 115M
totalInvestments 0 5M 5M 5M 5M 5M 5M 5M 0 0 0 0 0 0
totalDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 46M
netDebt -5M -3M -3M -3M -5M -6M -8M -9M -6M -7M -13M -20M -54M -9M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-05 2023-03-22 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 556 000 0 96 000 100 000 127 000
otherReceivables 0 0 0 0 0
prepaids 421 000 442 000 805 000 0 2M
totalPayables 390 000 1M 3M 2M 1M
otherPayables 0 0 0 0 0
accruedExpenses 272 000 786 000 5M 2M 9M
capitalLeaseObligationsCurrent 0 0 0 0 3M
capitalLeaseObligationsNonCurrent 0 0 0 0 39M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 276M 270M 263M 223M
otherTotalStockholdersEquity 276M 0 -0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-05 2024-11-14 2024-08-07 2024-05-07 2023-11-13 2023-07-28 2023-05-12 2022-11-03
acceptedDate 2025-11-12 16:30:53 2025-08-05 16:30:55 2025-03-04 16:15:24 2024-11-14 16:30:24 2024-08-07 06:45:21 2024-05-07 16:30:34 2024-03-05 16:15:38 2023-11-13 16:30:32 2023-07-28 16:48:38 2023-05-11 19:37:17 2023-03-22 16:55:38 2022-11-03 17:00:58 2022-02-24 16:06:04 2021-02-25 07:35:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -976 000 -324 000 -3M -723 000 -1M -2M -13M 8M -4M -7M -18M -10M -52M -78M
depreciationAndAmortization 0 0 0 0 0 0 0 0 0 0 65 000 0 472 000 2M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 118 000 114 000 625 000 138 000 184 000 181 000 0 159 000 379 000 426 000 0 2M 10M 15M
changeInWorkingCapital 594 000 -293 000 -2M 478 000 32 000 -510 000 -5M -2M -3M 314 000 -3M -1M 1M -8M
accountsReceivables 425 000 56 000 -556 000 -44 000 0 0 96 000 0 96 000 0 4000 0 27 000 1M
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 18 000 -21 000 -445 000 184 000 -91 000 -456 000 -2M -1M -2M 955 000 1M -1M 393 000 -1M
otherWorkingCapital 151 000 -328 000 -537 000 338 000 123 000 -54 000 -3M -1M -788 000 -641 000 -4M 41 000 988 000 -8M
otherNonCashItems 0 0 -363 000 -2M 0 637 000 -4M -12M 0 0 -20M 0 4M -4M
netCashProvidedByOperatingActivities -264 000 -503 000 -4M -2M -1M -2M -21M -7M -7M -6M -41M -10M -37M -72M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 0 0 0 0 0 -7000 -2M
acquisitionsNet 0 0 0 0 0 0 10M 10M 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 0 10M 0 0 0
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 2M -130 000 0 0 0 0 5M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 0 0 0 0 0 0 0
netCashUsedProvidedByFinancingActivities 2M -130 000 0 0 0 0 5M 0 0
effectOfForexChangesOnCash 0 0 -6000 0 -2000 -4000 8000 0 3000 1000 3000 -3000 4000 -7000
netChangeInCash 2M -633 000 -4M -2M -1M -2M -6M 3M -2M -6M -41M -10M -4M -44M
cashAtEndOfPeriod 5M 3M 3M 3M 5M 6M 8M 9M 6M 7M 13M 20M 54M 58M
cashAtBeginningOfPeriod 3M 4M 8M 5M 6M 8M 13M 6M 7M 13M 54M 30M 58M 103M
operatingCashFlow -264 000 -503 000 -4M -2M -1M -2M -21M -7M -7M -6M -41M -10M -37M -72M
capitalExpenditure 0 0 0 0 0 0 0 0 0 0 0 0 -7000 -2M
freeCashFlow -264 000 -503 000 -4M -2M -1M -2M -21M -7M -7M -6M -41M -10M -37M -74M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-05 2023-03-22 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 1M 2M
netCashProvidedByInvestingActivities 0 10M 0 1M 18 000
netDebtIssuance 0 0 0 0 4M
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 4M
netStockIssuance 0 5M 29 000 31M 24M
netCommonStockIssuance 0 5M 29 000 31M 24M
commonStockIssuance 0 5M 29 000 31M 24M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 282 000 331 000
netCashProvidedByFinancingActivities 0 5M 29 000 31M 28M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2026-01-06 13:33 ET
Cyclerion Therapeutics published news for 2025 q4
SEC form 8
2026-01-06 13:33 ET
Cyclerion Therapeutics published news for 2025 q4
SEC form 8
2026-01-06 13:33 ET
Cyclerion Therapeutics published news for 2025 q4
SEC form 10
2025-11-12 16:30 ET
Cyclerion Therapeutics reported for 2025 q3
SEC form 8
2025-09-23 20:14 ET
Cyclerion Therapeutics published news for 2025 q2
SEC form 8
2025-09-23 20:14 ET
Cyclerion Therapeutics published news for 2025 q2
SEC form 8
2025-09-23 20:14 ET
Cyclerion Therapeutics published news for 2025 q2
SEC form 10
2025-08-05 20:30 ET
Cyclerion Therapeutics reported for 2025 q2
SEC form 8
2025-06-18 20:41 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 8
2025-05-07 21:25 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 8
2025-05-07 21:25 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 8
2025-05-07 21:25 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 10
2025-05-06 20:15 ET
Cyclerion Therapeutics reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Cyclerion Therapeutics reported for 2025 q1
SEC form 8
2025-03-25 20:40 ET
Cyclerion Therapeutics published news for 2024 q4
SEC form 8
2025-03-25 20:40 ET
Cyclerion Therapeutics published news for 2024 q4
SEC form 8
2025-03-25 20:40 ET
Cyclerion Therapeutics published news for 2024 q4
SEC form 10
2025-03-04 21:15 ET
Cyclerion Therapeutics reported for 2024 q4
SEC form 10
2025-03-04 00:00 ET
Cyclerion Therapeutics reported for 2024 q4
SEC form 10
2024-11-14 16:30 ET
Cyclerion Therapeutics reported for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Cyclerion Therapeutics reported for 2024 q3
SEC form 10
2024-08-07 00:00 ET
Cyclerion Therapeutics reported for 2024 q2
SEC form 10
2024-05-07 00:00 ET
Cyclerion Therapeutics reported for 2024 q1
SEC form 10
2024-03-05 00:00 ET
Cyclerion Therapeutics reported for 2023 q4
SEC form 10
2023-11-13 00:00 ET
Cyclerion Therapeutics reported for 2023 q3
SEC form 10
2023-07-28 16:48 ET
Cyclerion Therapeutics reported for 2023 q2
SEC form 10
2023-07-28 00:00 ET
Cyclerion Therapeutics reported for 2023 q2
SEC form 6
2023-07-19 17:27 ET
Cyclerion Therapeutics published news for 2023 q2
SEC form 6
2023-07-12 16:12 ET
Cyclerion Therapeutics published news for 2023 q2
SEC form 6
2023-06-27 16:53 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-06-09 17:23 ET
Cyclerion Therapeutics reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
Cyclerion Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 19:37 ET
Cyclerion Therapeutics reported for 2023 q1
SEC form 6
2023-05-11 19:26 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-04-03 16:32 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-04-03 09:53 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-03-22 17:00 ET
Cyclerion Therapeutics published news for 2022 q4
SEC form 10
2023-03-22 16:55 ET
Cyclerion Therapeutics reported for 2022 q4
SEC form 6
2023-03-22 16:52 ET
Cyclerion Therapeutics published news for 2022 q4
SEC form 10
2023-03-22 00:00 ET
Cyclerion Therapeutics reported for 2022 q4
SEC form 8
2023-03-22 00:00 ET
Cyclerion Therapeutics published news for 2022 q4
SEC form 6
2022-11-29 16:00 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 6
2022-11-22 16:31 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 17:00 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Cyclerion Therapeutics reported for 2022 q3
SEC form 6
2022-10-06 08:01 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 6
2022-09-30 17:15 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 16:04 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-08-09 16:01 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Cyclerion Therapeutics reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-07-28 09:00 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-07-26 16:30 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-07-26 07:00 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-06-15 16:03 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 07:01 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-06-03 16:00 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 16:07 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-05-04 16:01 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Cyclerion Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-04-26 07:52 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 10
2022-02-24 16:06 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 6
2022-02-24 16:01 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 6
2021-12-10 16:32 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-12-10 16:31 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-12-10 16:31 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 16:01 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-11-09 16:01 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-10-28 16:50 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-09-30 09:01 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-27 16:40 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-27 16:37 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-27 16:31 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-19 16:51 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 10
2021-07-29 16:58 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-07-29 16:54 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-06-28 17:27 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:25 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:22 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:17 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:14 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:11 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:05 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-25 16:31 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-04 16:37 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-05-19 18:16 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-05-06 21:27 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-05-04 16:39 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 10
2021-04-30 16:04 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 07:01 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-04-27 09:20 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-04-26 08:58 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-03-19 06:01 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-03-18 17:00 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 10
2021-02-25 07:35 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-01-13 07:31 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 17:49 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 17:45 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2020-12-30 21:53 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 6
2020-12-21 16:35 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 07:00 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 6
2020-10-14 07:22 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 6
2020-10-01 07:21 ET
Cyclerion Therapeutics published news for 2020 q3